Loading…
Propanc Biopharma, Inc. is projected to decline to $1.48 by 2027, a -8% move from its current price of $1.61. PPCB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.47 | $1.61 | $1.77 | +0.07% |
| Jul 14 | $1.41 | $1.61 | $1.84 | +0.14% |
| Jul 15 | $1.37 | $1.61 | $1.89 | +0.21% |
| Jul 16 | $1.34 | $1.61 | $1.94 | +0.27% |
| Jul 17 | $1.31 | $1.62 | $1.99 | +0.34% |
| Jul 18 | $1.29 | $1.62 | $2.03 | +0.41% |
| Jul 19 | $1.27 | $1.62 | $2.07 | +0.48% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.27 | $1.62 | $2.07 | +0.48% |
| Week 2 | $1.15 | $1.63 | $2.30 | +0.96% |
| Week 3 | $1.07 | $1.63 | $2.50 | +1.45% |
| Week 4 | $1.00 | $1.64 | $2.68 | +1.93% |
| Week 5 | $0.9519 | $1.65 | $2.86 | +2.42% |
| Week 6 | $0.9076 | $1.66 | $3.02 | +2.91% |
| Week 7 | $0.869 | $1.66 | $3.19 | +3.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Propanc Biopharma, Inc. is a development-stage biopharmaceutical healthcare company that develops cancer treatments for pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention, which has completed pre-clinical studies.
The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. It was incorporated in 2007 and is based in Camberwell, Australia.
It has research and collaboration agreements with the University of Jaén to undertake research activities for the POP1 Program and with the University of Granada to develop a synthetic recombinant version of PRP."
Propanc Biopharma, Inc. trades under the PPCB ticker. The current price is $1.77 and the market cap is $4.03M, with a rank of 5225. The price outlook is mixed in the near term but shows rising potential over the longer horizon according to the year-by-year forecast.
The short- to long-range forecast depicts a path from 2026 to 2050 with multiple bullish years and notable upside by 2050, though some early years show flat or modest results. The forecast highlights a broad potential upside, culminating in a 2050 average price of $7.43 and a max of $17.08, delivering an estimated 319.6% ROI over that span."
A major floor 55.5% below — a decisive break under it would weaken the trend.
The nearest floor, 16.1% below — buyers have tended to step in here.
The nearest ceiling, 50.9% above — a clean break opens room to run.
A major ceiling 168.2% above — clearing it would confirm fresh momentum.
Key PPCB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PPCB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.78 | Sell | $1.71 | Sell |
| MA 10 | $1.67 | Sell | $1.69 | Sell |
| MA 20 | $1.73 | Sell | $1.70 | Sell |
| MA 50 | $1.87 | Sell | $2.11 | Sell |
| MA 100 | $2.65 | Sell | $5.73 | Sell |
| MA 200 | $12.77 | Sell | $19.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.76 | Neutral |
| Stoch RSI (14) | 38.08 | Neutral |
| CCI (20) | -34.53 | Neutral |
| Williams %R (14) | -61.36 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 9.52 | Buy |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 38.64 | Neutral |
| TRIX (15) | -0.60 | Sell |
| Awesome (5,34) | 0.09 | Buy |
| Ultimate (7,14,28) | 55.56 | Neutral |
| Momentum (10) | 0.10 | Buy |
| Aroon Osc (25) | 4.00 | Buy |
| Hull MA (9) | 1.80 | Sell |
| ADX (14) | 15.06 | Neutral |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is neutral. The RSI14 sits at 50, signaling balanced momentum near the midpoint. The chart shows a 50-day simple moving average of $1.97 and a 200-day moving average of $14.08, indicating a wide gap between near-term price dynamics and the long-term trend.
Support is noted at $1.35 and resistance at $2.43. The 30-day price range spans from $0.8858 to $3.54, and annualized volatility is very high at 200%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.35 | $1.61 | $2.31 | 0% | Neutral | |
| $1.07 | $1.48 | $2.21 | -8% | Neutral | |
| $1.55 | $2.26 | $3.60 | +41% | Bullish | |
| $1.66 | $2.57 | $4.28 | +59% | Bullish | |
| $1.50 | $2.43 | $4.21 | +51% | Bullish | |
| $1.48 | $2.49 | $4.48 | +55% | Bullish | |
| $1.29 | $2.27 | $4.21 | +41% | Bullish | |
| $1.17 | $2.15 | $4.09 | +33% | Bullish | |
| $1.09 | $2.08 | $4.06 | +29% | Bullish | |
| $1.31 | $2.61 | $5.21 | +62% | Bullish | |
| $1.27 | $2.82 | $6.20 | +75% | Bullish | |
| $3.08 | $6.84 | $15.73 | +325% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.35 | $1.61 | $2.05 | +0.00% |
| August 2026 | $1.48 | $1.80 | $2.27 | +11.69% |
| September 2026 | $1.39 | $1.71 | $2.21 | -4.71% |
| October 2026 | $1.29 | $1.61 | $2.11 | -6.12% |
| November 2026 | $1.34 | $1.69 | $2.25 | +5.02% |
| December 2026 | $1.35 | $1.72 | $2.31 | +1.57% |
Click any year to see its month-by-month PPCB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PPCB is projected to trade between $1.35 and $2.31, averaging $1.61 — a potential gain of 0% from today's $1.61. Price action looks broadly range-bound.
Propanc Biopharma, Inc.'s 2027 outlook centres on $1.48, within a $1.07 to $2.21 range. That is -8% versus the projected 2026 average. That marks a -8% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, PPCB could reach as high as $3.60, with a base case around $2.26 and support toward $1.55 — roughly +41% from $1.61. Momentum favours further upside here.
Expect PPCB to range from $1.66 to $4.28 through 2029. The $2.57 average target implies a +59% move from current prices. That is up +13% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The PPCB price prediction for 2030 points to an average of $2.43 (low $1.50, high $4.21) — a potential gain of +51% on today's $1.61. Momentum favours further upside here.
In 2031, PPCB is projected to trade between $1.48 and $4.48, averaging $2.49 — a potential gain of +55% from today's $1.61. That is up +3% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Propanc Biopharma, Inc.'s 2032 outlook centres on $2.27, within a $1.29 to $4.21 range. That is -9% versus the projected 2031 average. That marks a +41% change versus current levels. Momentum favours further upside here.
By 2033, PPCB could reach as high as $4.09, with a base case around $2.15 and support toward $1.17 — roughly +33% from $1.61. Buyers look set to stay in control over this stretch.
Expect PPCB to range from $1.09 to $4.06 through 2034. The $2.08 average target implies a +29% move from current prices. That is -3% versus the projected 2033 average. Momentum favours further upside here.
The PPCB price prediction for 2035 points to an average of $2.61 (low $1.31, high $5.21) — a potential gain of +62% on today's $1.61. Buyers look set to stay in control over this stretch.
In 2040, PPCB is projected to trade between $1.27 and $6.20, averaging $2.82 — a potential gain of +75% from today's $1.61. That is up +8% on the projected 2035 average. Momentum favours further upside here.
Propanc Biopharma, Inc.'s 2050 outlook centres on $6.84, within a $3.08 to $15.73 range. That is up +142% on the projected 2040 average. That marks a +325% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in PPCB today (≈ 621.118012 PPCB) could be worth
$4,249.1
+$3,249.1 (+325%) by 2050 · US Dollar
Based on the average projected PPCB price of $6.84 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PPCBwould be worth at today's price.
$1,000 invested in PPCB on Jul 10, 2025 (≈ 6.666667 PPCB) would be worth
$10.73
-$989.27 (-98.9%) today · 0.01× · US Dollar
Based on a PPCB entry price of $150 vs. today's $1.61.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.77 | $909.6 | -9.0% |
| 1 month ago | $1.35 | $1,192.59 | +19.3% |
| 3 months ago | $2.58 | $625.24 | -37.5% |
| 6 months ago | $11.33 | $142.13 | -85.8% |
| 1 year ago | $150 | $10.73 | -98.9% |
| All time (5.0y) ago | $2,085 | $0.77 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PPCB forecast.
Our base-case forecast reaches $3.20 around 2050.
Implied market cap at $3.20: $7.29M
The multi-year forecast begins with a neutral stance in 2026 (min $1.35, avg $1.77, max $2.50; ROI 0; sentiment NEUTRAL) and remains neutral in 2027 (min $1.18, avg $1.63, max $2.43; ROI -8.1%; sentiment NEUTRAL). Beginning in 2028 the outlook turns bullish, with 2028 (min $1.74, avg $2.56, max $4.06; ROI 44.4%), 2029 (min $1.80, avg $2.79, max $4.65; ROI 57.4%), and 2030 (min $1.63, avg $2.63, max $4.57; ROI 48.8%) showing gains and a bullish sentiment. The forecast continues to show bullish momentum through 2031 (avg $2.81, max $5.05; ROI 58.7%), 2032 (avg $2.46, max $4.56; ROI 39%), 2033 (avg $2.32, max $4.42; ROI 31.1%), 2034 (avg $2.35, max $4.60; ROI 32.9%), and 2035 (avg $2.85, max $5.69; ROI 60.9%).
Looking further out, 2040 projects an average price of $3.18 with a max of $6.99 and an ROI of 79.8%, still within a bullish framework, and 2050 shows a dramatic rise to an average of $7.43, a max of $17.08, and an ROI of 319.6% with bullish sentiment. These figures illustrate a long-term bullish trajectory with substantial upside potential, tempered by the inherent uncertainty in future forecasts."
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $2.63, with a minimum of $1.63 and a maximum of $4.57. The ROI is projected at 48.8% and the sentiment is BULLISH.
Forecasts indicate neutral sentiment in 2026 and 2027, followed by bullish years from 2028 onward, with notable upside by 2040 (average around $3.18) and especially 2050 (average around $7.43, ROI 319.6%). These are estimates and not guarantees.
Yes. The forecast shows a max of $5.69 in 2035 and a max of $6.99 in 2040, suggesting reaching or surpassing $5 is within the projected maxima, though these are not guarantees.
Current price is $1.77 and market cap is $4.03M.
The 2050 forecast shows an average price of $7.43, a minimum of $3.34, a maximum of $17.08, and a ROI of 319.6%, with a bullish sentiment.
Propanc Biopharma, Inc. Community Discussion
0Share your Propanc Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.